Arrowhead Pharmaceuticals Inc. (ARWR)
ARWR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-09-30, https://www.sec.gov/Archives/edgar/data/879407/000087940726000078/0000879407-26-000078-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-09-30.
Profile
| Field | Value |
|---|---|
| Ticker | ARWR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000879407 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $450.8M |
| Net income | -$724.2M |
| Operating income | -$707.2M |
| Net margin | -160.6% |
| Operating margin | -156.9% |
| Revenue growth | -45.6% |
| Cash | $62.7M |
| Total assets | $1.7B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 13.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-K 2026-11-12 |
| Cash and burn | $62.7M cash; operating cash flow -$68.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 141,368,004 (2026-11-05); 135,809,558 a year earlier; 107,432,210 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the market | Latest 2026-01-09 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Diego, California, United States | PCAOB Form AP 2025-12-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $38.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q4 2026 2026-09-30 | $37.8M | -$428.0M | -$192.4M | $62.7M | $683.5M | $450.8M | 10-K 2026-11-12 |
| Q3 2026 2026-06-30 | $75.3M | -$194.3M | -$177.5M | $54.8M | $682.7M | $669.5M | 10-Q 2026-08-04 |
| Q2 2026 2026-03-31 | $73.7M | -$132.7M | $84.4M | $188.5M | $681.9M | $622.0M | 10-Q 2026-05-07 |
| Q1 2026 2025-12-31 | $264.0M | $30.8M | $13.5M | $201.6M | No debt tags | $1.1B | 10-Q 2026-02-05 |
| Q4 2025 2025-09-30 | $256.5M | -$23.8M | $20.5M | $226.5M | $0 | $829.4M | 10-K 2026-11-12 |
| Q3 2025 2025-06-30 | $27.8M | -$175.2M | -$154.7M | $129.8M | No debt tags | $573.0M | 10-Q 2026-08-04 |
| Q2 2025 2025-03-31 | $542.7M | $370.4M | $460.1M | $185.7M | No debt tags | $545.2M | 10-Q 2026-05-07 |
| Q1 2025 2024-12-31 | $2.5M | -$173.1M | -$146.3M | $53.9M | No debt tags | $2.5M | 10-Q 2026-02-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-01-09 |
| Latest annual report | 10-K | 2026-11-12 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-01-27 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -17.8% |
| 1 month | -17.8% |
| 3 months | -44.2% |
| Year to date | -28.0% |
| 1 year | +16.1% |
| From 52-week high | -46.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorporated | $301.71 | -2.29% | $6.0B |
| GRFS | Grifols S.A. | $8.73 | +0.46% | $6.0B |
| SUPN | Supernus Inc. | $28.83 | -2.99% | $6.0B |
| MIRM | Mirum Pharmaceuticals Inc. | $91.58 | -2.56% | $6.0B |
| BLTE | Belite Bio Inc | $162.56 | -1.09% | $6.5B |
| AXSM | Axsome Therapeutics Inc. | $137.01 | -3.30% | $7.2B |
| MANE | Veradermics Incorporated | $128.05 | -1.24% | $5.4B |
| ABVX | Abivax SA | $83.61 | -4.53% | $7.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier